| 3.02 3.02 (1.34%) | 04-17 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 6.7 | 1-year : | 9.9 |
| Resists | First : | 5.74 | Second : | 8.47 |
| Pivot price | 3.25  |
|||
| Supports | First : | 1.3 | Second : | 1.08 |
| MAs | MA(5) : | 3.02 |
MA(20) : | 2.83 |
| MA(100) : | 1.71 |
MA(250) : | 2.28 |
|
| MACD | MACD : | 0.3  |
Signal : | 0.4 |
| %K %D | K(14,3) : | 22.7 |
D(3) : | 23.2 |
| RSI | RSI(14): 53.8 |
|||
| 52-week | High : | 8.47 | Low : | 1.02 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ CYCN ] has closed above bottom band by 45.8%. Bollinger Bands are 380.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 11 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 3.02 - 3.04 | 3.04 - 3.06 |
| Low: | 2.8 - 2.82 | 2.82 - 2.84 |
| Close: | 2.99 - 3.02 | 3.02 - 3.05 |
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, as well as Alzheimer's disease with vascular pathology; and Phase 1 trials diagnosed with schizophrenia in adults. It is also developing Praliciguat, an orally administered systemic sGC stimulator, which is in Phase II studies to treat resistant hypertension and diabetic nephropathy; Olinciguat, an orally administered vascular sGC stimulator that is in Phase II studies for the sickle cell disease; and CY3018 for the treatment of disorders of the CNS. It has license agreement with Akebia Therapeutics, Inc. for the development, manufacture, medical affairs, and commercialization of pharmaceutical products, including pharmaceutical compound, and other related products and forms. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Thu, 02 Apr 2026
CYCN stock is soaring 150% pre-market today — what is fueling the rally? - MSN
Wed, 01 Apr 2026
Why is Biotech Stock Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) Gaining? - Investorideas.com
Wed, 01 Apr 2026
Cyclerion to Merge With Korsana; $380 Million PIPE, CVRs and Lock-Ups Support Deal - TradingView
Wed, 01 Apr 2026
Why is Cyclerion Therapeutics Stock (CYCN) Up Over 160% Today? - TipRanks
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 4 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 24.2 (%) |
| Held by Institutions | 7.2 (%) |
| Shares Short | 113 (K) |
| Shares Short P.Month | 94 (K) |
| EPS | -1.12 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.38 |
| Profit Margin | -170.2 % |
| Operating Margin | -81.8 % |
| Return on Assets (ttm) | -31.8 % |
| Return on Equity (ttm) | -39.4 % |
| Qtrly Rev. Growth | -43.3 % |
| Gross Profit (p.s.) | 0.25 |
| Sales Per Share | 0.47 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -3 (M) |
| Levered Free Cash Flow | -3 (M) |
| PE Ratio | -2.73 |
| PEG Ratio | 0 |
| Price to Book value | 1.26 |
| Price to Sales | 6.31 |
| Price to Cash Flow | -3.96 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|